Healthcare [ 13/13 ] | Diagnostics & Research [ 77/164 ]
NASDAQ | Common Stock
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer.
The company was incorporated in 2014 and is based in San Antonio, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 298.48 K Increased by +25.86 K% | -2.29 M Increased by +53.43% | Decreased by -767.51% Increased by +99.82% |
| Jun 30, 23 | 19.74 K Increased by +1.41 K% | -1.74 M Decreased by -257.09% | Decreased by -8.82 K% Increased by +76.37% |
| Mar 31, 23 | 921.00 Increased by +N/A% | -1.53 M Decreased by -4.13% | Decreased by -166.43 K% Decreased by N/A% |
| Dec 31, 22 | 2.35 K Increased by +N/A% | -1.68 M Increased by +69.93% | Decreased by -71.47 K% Decreased by N/A% |
| Sep 30, 22 | 1.15 K Increased by +N/A% | -4.92 M Decreased by -224.98% | Decreased by -427.78 K% Decreased by N/A% |
| Jun 30, 22 | 1.31 K Increased by +N/A% | -487.32 K Decreased by -132.92% | Decreased by -37.31 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -1.47 M Decreased by -105.54% | Decreased by N/A% - |
| Dec 31, 21 | 0.00 - | -5.58 M - | Decreased by N/A% - |